ClinicalTrials.gg
CompletedNCT07176728Updated Jun 5, 2026

A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.

A Phase 1 interventional study of BAY 3389934 and Matching Placebo / Diluent in Sepsis Associated Disseminated Intravascular Coagulation (DIC), sponsored by Bayer. Completed at 2 sites in Japan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Sepsis with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Sepsis · Japan.

Enrollment
12th of 13
16 · median 203
Started
2025
the only one that year
Phase 1
2 of 17
none open now
Registered
16th of 17
by date
Lead sponsor
4 of 17
Bayer

Among the 17 studies in Sepsis with a site in Japan, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1, and was the 16th registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

1 of the 17 studies in Sepsis with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 319 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sepsis with a site in Japan, or all of them as a file.
02

Study summary

This study is designed to evaluate a new investigational drug, BAY 3389934, in healthy Japanese volunteers. The primary purpose is to see how safe the drug is and how well it is tolerated by the body when given at different doses. BAY 3389934 is being developed for the potential treatment of a serious blood clotting condition called sepsis-associated disseminated intravascular coagulation (DIC). The research will be conducted as a single-blind, placebo-controlled, dose-escalation study. This means that participants will be randomly assigned to receive either the active drug (BAY 3389934) or a placebo (an inactive substance), and they will not know which one they are receiving. The study will involve up to 16 healthy male and female Japanese participants, aged between 18 and 55. The study consists of two parts, called dose steps. In the first step, participants will receive a single 4-hour intravenous (IV) infusion of BAY 3389934 at a dose of 15 mg/h, or a placebo. Based on the safety and tolerability results from this first step, a second, higher dose will be selected for the next group of participants in the second step. Throughout the study, researchers will closely monitor participants for any side effects (adverse events). They will also collect blood and urine samples to study how the drug is absorbed, distributed, and eliminated by the body (pharmacokinetics or PK) and what effects it has on the body's clotting system (pharmacodynamics or PD). This involves measuring specific substances in the blood, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT). Participants will stay at the study center for 4 days and will have a follow-up visit 3 to 5 days after they are discharged. The information gathered from this study is crucial for the future clinical development of BAY 3389934 in Japan and for designing future studies in patients with septic DIC.

03

Conditions studied

  • Sepsis Associated Disseminated Intravascular Coagulation (DIC)

Keywords

  • Sepsis, Disseminated Intravascular Coagulation, Coagulopathy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive.

    • Participants who are overtly healthy Japanese as determined by medical evaluation.
    • (BMI) within the range 18 - 29.9 kg/m² (inclusive).
    • Male participants must agree to use specified during the study and for at least 90 days plus 5 half-lives after.
    • Female participants must be a Woman of Nonchildbearing Potential (WONCBP).
    • Capable of giving signed .
    • Willing to comply with the requirements and restrictions listed in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Any medical disorder, condition, or history that would impair participation.

    • Known to the study drug or its .
    • Known disorders with increased bleeding risk or known congenital/acquired coagulation disorders.
    • Use of prescription drugs, over-the-counter drugs, or herbal products within 14 days or 5 half-lives before the study.
    • findings in the , such as a over 450 msec.
    • Systolic blood pressure below 90 mmHg or above 140 mmHg at screening and admission.
    • Diastolic blood pressure below 40 mmHg or above 90 mmHg at screening and admission.
    • Positive results for , , or .
    • Positive drug screening, alcohol breath test, or urine cotinine test.
    • Clinically relevant deviations of the screened laboratory parameters from reference ranges at the screening visit.
    • Positive pregnancy test.
    • Donation of blood or plasma within specified timeframes before the study.
    • Lack of compliance with lifestyle restrictions (e.g., alcohol, specific foods, strenuous activity).
    • Previous participation in this or another clinical study within a specified timeframe.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Dose Step 1 BAY 3389934

    15 mg/h/ intravenous Single Dose for 4 h fasting

    Drug: BAY 3389934

  • Experimental
    Dose Step 2 BAY 3389934

    Max. dose 35 mg / h / intravenous - actual dose will be determined after Dose Step 1 Single Dose for 4 h fasting

    Drug: BAY 3389934

  • Placebo comparator
    Dose Step 1 and Dose Step 2 Placebo

    Placebo / intravenous Single Dose for 4 h Fasting

    Drug: Matching Placebo / Diluent

Interventions

  • Solution for intravenous infusion

  • DrugMatching Placebo / Diluent

    Solution for intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Investigate the safety and tolerability of BAY 3389934 15 mg/h and a second, higher dose (will be determined based on the result of 15 mg/h dose step), 4-hours infusion, respectively.

    Time frame: From start of study intervention until the follow-up visit (approximately 5 weeks)

Secondary outcomes

  1. Pharmacokinetic (PK) Profile of BAY 3389934 - Cmax

    Maximum observed drug concentration (Cmax) within the given timeframe. PK parameters will be calculated using the non-compartmental method according to the sponsor's current guidelines using PhoenixTM (Certara, Princeton, New Jersey).

    Time frame: From pre-dose (0 hours) up to 48 hours after start of infusion

  2. Pharmacokinetic (PK) Profile of BAY 3389934 - AUC

    Area under the concentration vs. time curve from zero to infinity (AUC) within the given timeframe. In the case of an unexpected event of e.g., an exceedingly large (\>20%) extrapolated portion of AUC (AUC(tlast-∞)), the parameter AUC(0-tlast) may be evaluated as main parameter. PK parameters will be calculated using the non-compartmental method according to the sponsor's current guidelines using PhoenixTM (Certara, Princeton, New Jersey).

    Time frame: From pre-dose (0 hours) up to 48 hours after start of infusion

  3. Pharmacokinetic (PK) Profile of BAY 3389934 - Cmax/D

    Maximum observed drug concentration (Cmax) divided by dose (Cmax/D) within the given timeframe. PK parameters will be calculated using the non-compartmental method according to the sponsor's current guidelines using PhoenixTM (Certara, Princeton, New Jersey).

    Time frame: From pre-dose (0 hours) up to 48 hours after start of infusion

  4. Pharmacokinetic (PK) Profile of BAY 3389934 - AUC/D

    Area under the concentration vs. time curve from zero to infinity (AUC) divided by dose (AUC/D) in the given timeframe. In the case of an unexpected event of e.g., an exceedingly large (\>20%) extrapolated portion of AUC (AUC(tlast-∞)), the parameter AUC(0-tlast) may be evaluated as main parameter. PK parameters will be calculated using the non-compartmental method according to the sponsor's current guidelines using PhoenixTM (Certara, Princeton, New Jersey).

    Time frame: From pre-dose (0 hours) up to 48 hours after start of infusion

  5. Pharmacokinetic (PK) Profile of BAY 3389934 - t 1/2

    Half-life associated with the terminal slope (t1/2) of BAY 3389934 in plasma within the given timeframe. PK parameters will be calculated using the non-compartmental method according to the sponsor's current guidelines using PhoenixTM (Certara, Princeton, New Jersey).

    Time frame: From pre-dose (0 hours) up to 48 hours after start of infusion

  6. Pharmacodynamic (PD) Profile of BAY 3389934 - aPTT

    Measure Activated partial thromboplastin time (aPTT). Assessed as the maximal ratio to baseline and the ratio to baseline at 4 hours and 5 hours after beginning of infusion.

    Time frame: From pre-dose up to 5 hours after beginning of infusion.

  7. Pharmacodynamic (PD) Profile of BAY 3389934 - PT

    Prothrombin time (PT). Assessed as the maximal ratio to baseline and the ratio to baseline at 4 hours and 5 hours after beginning of infusion.

    Time frame: From pre-dose up to 5 hours after beginning of infusion.

07

Study locations

2 sites
  • SOUSEIKAI Fukuoka Mirai Hospital
    Fukuoka, Fukuoka Pref 813-0017, Japan
  • SOUSEIKAI Fukuoka Mirai Hospital
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in May 2026, 7 months.

Of 32 phase 1 interventional studies under Sepsis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 16, 2025
StartActual
Sep 22, 2025
Primary completionActual
May 17, 2026
CompletionActual
May 17, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176728
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Sep 22, 2025
Primary completion
May 17, 2026
Completion
May 17, 2026
Last update
Jun 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BAY 3389934

Start the discussion